Bajaj Finserv ELSS - Tax Saver Fund
The scheme seeks to generate long term capital appreciation from a diversified portfolio of predominantly equity and equity related securities while offering deduction on such investment made in the scheme under Section 80C of the Income Tax Act, 1961.
Growthvine rating: 1/5 — ranked #50 of 57 in category.
Fund basics
| Category | Equity: ELSS |
|---|
| NAV | ₹10.84 (as of 2026-10-22) |
|---|
| AUM | ₹88 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nimesh Chandan |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −14.08% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 102.5% of Nifty 500's upside and 102.0% of its downside.
Market cap allocation
| Large cap | 46.1% |
|---|
| Mid cap | 14.3% |
|---|
| Small cap | 39.6% |
|---|
Concentration
| Top 5 holdings | 31.5% |
|---|
| Top 10 holdings | 47.6% |
|---|
| Total holdings | 42 |
|---|
| Index overlap | 24.2% |
|---|
| Active share | 75.8% |
|---|
Top holdings
- HDFC Bank Ltd. — 9.2%
- Clearing Corporation of India Ltd — 8.3%
- ICICI Bank Ltd. — 6.4%
- Reliance Industries Ltd — 5.8%
- Divis Laboratories Ltd. — 5.6%
- Zydus Wellness Limited — 4.7%
- State Bank Of India — 4.1%
- Steel Authority of India Ltd. — 3.8%
- PG Electroplast Limited — 2.8%
- Balrampur Chini Mills Ltd. — 2.7%
Top sectors
- Banking & Financial — 22.0%
- Cash — 10.4%
- Pharma & Biotech — 7.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −5.1% | Q2 | #17 of 52 |